Shares of Fate Therapeutics Inc. (FATE) were up over 20 percent in extended trading on Thursday, following a worldwide collaboration with Johnson & Johnson subsidiary (JNJ) Janssen for novel induced pluripotent stem cell-derived cell-based cancer immunotherapies.
from RTT - Biotech https://ift.tt/3aF57ij
via IFTTT
No comments:
Post a Comment